Search

Displaying results 6581 - 6590 of 10000 in total
  1. Drug

    Acremonium strictum

    go.drugbank.com/drugs/DB10423
    ApprovedWithdrawn

    Acremonium strictum extract is used in allergenic testing.

  2. Drug

    Phoma glomerata

    go.drugbank.com/drugs/DB10700
    Approved

    Phoma glomerata extract is used in allergenic testing.

  3. Drug

    Neurospora crassa

    go.drugbank.com/drugs/DB10821
    Approved

    Neurospora crassa extract is used in allergenic testing.

  4. Drug

    Trichophyton verrucosum

    go.drugbank.com/drugs/DB11295
    Approved

    Trichophyton verrucosum extract is used in allergenic testing.

  5. Drug

    Lucitanib

    go.drugbank.com/drugs/DB11845
    Investigational

    Lucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.

  6. Drug

    TCB-008

    go.drugbank.com/drugs/DB18352
    Investigational

    TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.

  7. Drug

    Palmitic Acid

    go.drugbank.com/drugs/DB03796
    ApprovedInvestigational

    A common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.

    Mixtures: Huile D'onagre Vitamin E
  8. Drug

    Eprinomectin

    go.drugbank.com/drugs/DB11405
    ExperimentalVet approved

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    An animal study in mice fed a fast-food diet with TM5614 treatment showed improved metabolic measurements and reduced liver steatosis[L31673,L31678]. … Further investigation of this compound is underway, including an exploratry Phase II study for its efficacy and safety for high-risk hospitalized patients with severe COVID-19 pneumonia[L31688].

  10. Drug

    Verubecestat

    go.drugbank.com/drugs/DB12285
    Investigational

    In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of … In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat.